FOLH1 and prostate carcinoma: Recently, attempts have been made to utilize this to treat salivary tumors (usually adenoid cystic carcinoma or salivary duct cancer) with PSMA-targeted theranostic agents [39], particularly given the success of 177Lu-PSMA-617 for prostate cancer in the VISION [40] and TheraP trials [41].